Compare FPF & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPF | URGN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 922.1M |
| IPO Year | N/A | 2016 |
| Metric | FPF | URGN |
|---|---|---|
| Price | $17.86 | $18.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 133.1K | ★ 592.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,128,000.00 |
| Revenue This Year | N/A | $127.17 |
| Revenue Next Year | N/A | $73.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.32 | $3.42 |
| 52 Week High | $19.75 | $30.00 |
| Indicator | FPF | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 49.30 |
| Support Level | N/A | $18.37 |
| Resistance Level | $18.88 | $20.44 |
| Average True Range (ATR) | 0.33 | 0.93 |
| MACD | 0.02 | 0.18 |
| Stochastic Oscillator | 49.24 | 75.52 |
First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.